Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1111 AL 1125

Is there a need to redefine Parkinson's disease?

Mahlknecht P, Poewe W.

J Neural Transm (Vienna). 2013 Sep;120 Suppl 1:S9-17. doi: 10.1007/s00702-013-1038-5. Epub 2013 May 29.

Aberrant protein s-nitrosylation in neurodegenerative diseases

Nakamura T, Tu S, Akhtar MW, Sunico CR, Okamoto S, Lipton SA.

Neuron. 2013 May 22;78(4):596-614. doi: 10.1016/j.neuron.2013.05.005.

Mediterranean diet, stroke, cognitive impairment, and depression: A meta-analysis

Psaltopoulou T, Sergentanis TN, Panagiotakos DB, Sergentanis IN, Kosti R, Scarmeas N.

Ann Neurol. 2013 Oct;74(4):580-91. doi: 10.1002/ana.23944. Epub 2013 Sep 16.

Parkinson disease and exercise

Earhart GM, Falvo MJ.

Compr Physiol. 2013 Apr;3(2):833-48. doi: 10.1002/cphy.c100047.

Potential beneficial effects of marine peptide on human neuron health

Ryu B, Kim SK.

Curr Protein Pept Sci. 2013 May;14(3):173-6. doi: 10.2174/13892037113149990043.

The role of DNA repair in brain related disease pathology

Canugovi C, Misiak M, Ferrarelli LK, Croteau DL, Bohr VA.

DNA Repair (Amst). 2013 Aug;12(8):578-87. doi: 10.1016/j.dnarep.2013.04.010. Epub 2013 May 27.

Two young women with chronic daily headache and cognitive impairment: why we need to ask about headache in the postpartum period

Beams JL, Rozen TD.

Obstet Med. 2013 Jun;6(2):83-87. doi: 10.1177/1753495X13481771. Epub 2013 May 3.

Swallowing and deep brain stimulation in Parkinson's disease: a systematic review

Troche MS, Brandimore AE, Foote KD, Okun MS.

Parkinsonism Relat Disord. 2013 Sep;19(9):783-8. doi: 10.1016/j.parkreldis.2013.05.001. Epub 2013 May 28.

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K.

Lancet Neurol. 2013 Aug;12(8):747-55. doi: 10.1016/S1474-4422(13)70117-0. Epub 2013 May 31.

SOD2 in mitochondrial dysfunction and neurodegeneration

Flynn JM, Melov S.

Free Radic Biol Med. 2013 Sep;62:4-12. doi: 10.1016/j.freeradbiomed.2013.05.027. Epub 2013 May 29.

What basal ganglia changes underlie the parkinsonian state? The significance of neuronal oscillatory activity

Quiroga-Varela A, Walters JR, Brazhnik E, Marin C, Obeso JA.

Neurobiol Dis. 2013 Oct;58:242-8. doi: 10.1016/j.nbd.2013.05.010. Epub 2013 May 30.

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, Whitton P, Wyse R, Isaacs T, Lees A, Limousin P, Foltynie T.

J Clin Invest. 2013 Jun;123(6):2730-6. doi: 10.1172/JCI68295.

Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items"

Fabbrini G, Abbruzzese G, Barone P, Antonini A, Tinazzi M, Castegnaro G, Rizzoli S, Morisky DE, Lessi P, Ceravolo R; REASON study group.

Neurol Sci. 2013 Nov;34(11):2015-22. doi: 10.1007/s10072-013-1438-1. Epub 2013 Jun 1.

Prefrontal dopamine signaling and cognitive symptoms of Parkinson's disease

Narayanan NS, Rodnitzky RL, Uc EY.

Rev Neurosci. 2013;24(3):267-78. doi: 10.1515/revneuro-2013-0004.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias